Disc Medicine (NASDAQ:IRON) shares are having a fantastic year so far. The stock has risen in value by >165%, and is currently priced at $47, valuing the company at $934m at the time of writing. The hematologic disease specialist obtained its Nasdaq listing via a reverse-merger with Gemini Therapeutics, a failing, SPAC-listed biotech in the midst of a strategic review, beginning trading on a 1-10 reverse split basis on 30th December 2022. Disc was able to raise $53.5 from numerous biotech venture capital firms including OrbiMed, Atlas Ventures, 5AM Ventures, Novo Holdings, Arix Bioscience, Rock Springs Capital, and Janus Henderson.